CML with De Novo NPM1 Mutation and Rapid Progression to Myeloid Blast Cri-Sis despite Treatment with Imatinib: A Case Report

In this case we present a 41 year old male with chronic myeloid leukaemia who despite scoring low risk for Sokal progressed rapidly to blast crisis without warning and after having achieved partial response Imatinib therapy. We investigated using retrospective Next Generation Sequencing (NGS) identified novel NPM1 mutation at diagnosis together. also found tyrosine kinase domain mutations NGS not Sanger sequencing. believe highlights the effectivity of in identifying existing higher sensitivity, which could help improve practice prognostication management CML disease patients responding treatment adequately.